期刊
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
卷 26, 期 2, 页码 69-74出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/YIC.0b013e328340775e
关键词
antidepressant; major depressive disorder; medical co-morbidity; placebo
资金
- Bristol-Myers Squibb Company
- Forest Pharmaceuticals
- National Institute of Mental Health
- PAMLAB LLC
- Pfizer Inc.
- Ridge Diagnostics (formerly known as Precision Human Biolaboratories)
The objective of this study is to assess whether the antidepressants are effective in treating major depressive disorder (MDD) in patients with a co-morbid axis-III disorder, and to compare the relative efficacy (vs. placebo) of antidepressants between these patients and those enrolled in general MDD trials. Medline/Pubmed publication databases were searched. We selected for randomized, double-blind, placebo-controlled trials of antidepressants for MDD, whether conducted in a general population, or in populations with an axis-III disorder. Antidepressants were more effective than placebo in patients with axis-III disorders overall [risk ratio for response (RR) = 1.42, P < 0.0001], as well as specifically for post-stroke (RR = 1.43, P = 0.04), human-immunodeficiency virus positive or acquired immunodeficiency syndrome (RR = 1.66, P = 0.005), but not cancer patients (RR = 1.26, P = 0.19). There was a trend for higher placebo response rates in studies, which did (41.2%) versus those which did not (37.7%) select for axis-III disorders (P = 0.06), and significantly higher antidepressant response rates in studies which did (57.4%) versus those which did not (53.5%) select for axis-III disorders (P = 0.01). Antidepressants are effective for MDD in patients who present with co-morbid axis-III disorders and as effective (vs. placebo) in this population as they are in the general MDD population. Higher general response rates observed in the co-morbid MDD population are intriguing, and require replication. Int Clin Psychopharmacol 26:69-74 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据